JPRN-UMIN000003410已完成4 期
Peginterferon-alpha plus ribavirin therapy following twice-daily administration of interferon-beta in patients with genotype 1 and high viral load. - Peginterferon-alpha plus ribavirin therapy following twice-daily administration of interferon-beta in patients with genotype 1 and high viral load.
Gunma Liver Study Group0 个研究点目标入组 35 人开始时间: 2010年4月1日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients with autoimmune hepatitis. Pregnant woman, woman of child-bearing potential, or breast-feeding woman. Patients and thier partners who cannot use birth control durinf therapy and for 6 months after end of administration. Patients with hypersensitivity to ribavirin, or other nucleoside analogs. Patients with uncontrollable heart failure. Patients with hemoglobinopathy. Patinets with chronic renal failure and compromised renal function (equal to or less than 50mL/min of creatinine clearance. Patients with severe depression or psychiatric disease including suicide attempt or with history of suicide attempt. Patients with severe liver dysfunction. Patients with hypersensitivity to biological drug such as vaccine. Patients with hypersensitivity to interferon and bovine-derived material. Patients with interstitial pneumonia. Patients with a history of drug sensitivity or with allergic tendency. Patients administrated with Syousaikotou. Patients with being disqualified by the doctor. Patients who received peginterferon plus ribavirin therapy.
研究者
相似试验
进行中（未招募）
不适用
Peginterferon alfa-2a and Ribavirin Combination Therapy in Patients with HBeAg-negative Chronic HBV Infection - PARC studyEUCTR2004-004736-30-ATErasmus MC122
进行中（未招募）
不适用
Peginterferon alfa-2a and Ribavirin Combination Therapy in Patients with HBeAg-negative Chronic HBV Infection - PARC studychronic HBeAg-negative hepatitis BEUCTR2004-004736-30-DEFoundation of Liver research122
进行中（未招募）
不适用
COMBINED THERAPY WITH PEG-INTERFERON-a, RIBAVIRIN AND RITUXIMAB OF HEPATITIS C VIRUS-RELATED MIXED CRYOGLOBULINEMIA - NDpatients anti-HCV, HCV RNA positivity, Na?ve, with cryoglobulinemic vasculitis (detection of serum cryoglobulins associated with purpura, arthralgias and weakness)and with chronic hepatitisMedDRA version: 9.1Level: SOCClassification code 10005329EUCTR2010-020659-30-ITAZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE
进行中（未招募）
不适用
Treatment with Peg-interferon alfa-2a and ribavirin in patients with hepatitis HCV-related, with or without HIV co-infection, and end stage renal disease on dialysis - NDChonic hepatitis HCV-relatedMedDRA version: 9.1Level: SOCClassification code 10019805MedDRA version: 9.1Level: SOCClassification code 10038359EUCTR2010-023245-30-ITISTITUTO NAZIONALE DELLE MALATTIE INFETTIVE LAZZARO SPALLANZANI
已完成
不适用
Efficacy of pegylated interferon plus ribavirin lead-in therapy on telaprevir with pegylated interferon plus ribavirin therapy for aged patients with chronic hepatitis C genotype 1Chronic hepatitis CJPRN-UMIN000007329Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine410